Table 2.
Clinical, laboratory and imaging findings at the time of SARS-CoV-2 infection (data is presented as percentage of children with information available).
| Allo-HCT | |||||||
|---|---|---|---|---|---|---|---|
| Total | Auto | Allo total | ICU admissiona | Dieda | Severe coursea | P value | |
| Numbers | 89 | 4 | 85 | 9 (10) | 7 (8) | 11 (12) | |
| Clinical signs/symptoms at SARS-CoV-2 diagnosis | |||||||
| Symptomatic | |||||||
| Yes | 52/89 (58) | 0 (0) | 52/85 (61) | 9 (17) | 6 (12) | 10 (19) | 0.06 |
| No | 37/89 (42) | 4 (100) | 33/85 (39) | 0 (0) | 1 (3) | 1 (3) | |
| Fever | |||||||
| Yes | 37/88 (42) | 0 (0) | 37/84 (44) | 8 (22) | 5 (14) | 9 (24) | 0.01 |
| No | 51/88 (58) | 4 (100) | 47/84 (56) | 1 (2) | 2 (4) | 2 (4) | |
| Cough | |||||||
| Yes | 26/89 (29) | 0 (0) | 26/85 (31) | 8 (31) | 4 (15) | 8 (31) | 0.004 |
| No | 63/89 (71) | 4 (100) | 59/85 (69) | 1 (2) | 3 (5) | 3 (5) | |
| Upper respiratory symptomsb | 13/88 (15) | 0 (0) | 13/84 (15) | 1 (8) | 0 (0) | 1 (8) | |
| Fatigue | 11/88 (13) | 0 (0) | 11/84 (13) | 2 (18) | 1 (9) | 2 (18) | |
| Diarrhea | 9/88 (10) | 0 (0) | 9/84 (11) | 3 (33) | 2 (22) | 3 (33) | |
| Sputum production | 4/88 (5) | 0 (0) | 4/84 (5) | 2 (50) | 1 (25) | 2 (50) | |
| Other signs/symptomsc | 7/88 (8) | 0 (0) | 7/84 (8) | 3 (43) | 2 (29) | 3 (43) | |
| Time since start of symptoms to COVID-19 diagnosis in children symptomatic at diagnosis; median (range); days | 2 (0–40) n = 39 | n = 0 | 2 (0–40) n = 39 | 6(0–40) n = 9 | 3(0–10) n = 5 | 6(0–40) n = 9 | 0.1 |
| Coinfectiond | |||||||
| No | 64/88 (73) | 3 (75) | 61/84 (73) | 3 (5) | 2 (3) | 4 (7) | 0.009 |
| Yes | 24/88 (27) | 1 (25) | 23/84 (27) | 6 (26) | 5 (22) | 7 (30) | |
| Laboratory parameters at the time of diagnosis | |||||||
| Neutropenia <500 cells | 63/70 (90) | 3 (75) | 60/66 (91) | 9 (15) | 6 (10) | 10 (17) | 0.3 |
| Neutropenia <100 cells | 9/70 (13) | 0 (0) | 9/66 (14) | 2 (22) | 3 (33) | 3 (33) | 0.1 |
| Lymphopenia <500 cells | 62/68 (91) | 4 (100) | 58/64 (91) | 8 (14) | 4 (7) | 8 (14) | 0.2 |
| Lymphopenia <200 cells | 49/69 (71) | 3 (75) | 46/65 (71) | 6 (13) | 3 (7) | 6 (13) | 0.4 |
| C-reactive protein levels median (min-max), mg/Le | 5 (0.0–234) n = 67 | 6 (2–16) n = 4 | 5 (0.0–234) n = 63 | 14 (1–234) n = 9 | 66 (5–234) n = 6 | 15 (1–234) n = 10 | 0.04 |
| Pulmonary radiological findings | |||||||
| Yes | 18/62 (29) | 0 (0) | 18/60 (30) | 8 (44) | 4 (22) | 8 (44) | 0.004 |
| No | 44/62 (71) | 2 (100) | 42/60 (70) | 1 (2) | 3 (7) | 3 (7) | |
ICU intensive care unit.
aThe proportion of patients with ICU, mortality and severe course is presented within the group of allo-HCT patients with data available.
bUpper respiratory symptoms included rhinorrhea, sinusitis, otitis, or pharyngitis.
cOther: myalgia or arthralgia (4), conjunctivitis (3), vomiting (2), taste disturbance (1), smell disturbance (1), meningoencephalitis (1).
dSpecified in Supplementary Table 1.
eC-reactive protein in 53 allo-HCT patients with mild course was median (min-max) 3 (0–110) mg/L.
Bold entries indicate significant p values.